SERVIER
Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of LONSURF® (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy. The trial will continue as planned given that no deleterious effects and no new safety issues have been raised in either study arm.
Data from the primary analysis will be presented at an upcoming medical congress.
“We remain committed to improving outcomes in mCRC and we will continue to follow patients as planned in order to perform the main secondary endpoint analysis on overall survival in 2023,” said Patrick Therasse, M.D., Ph. D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier. “The clinical value of LONSURF in its current indications remains unchanged, and the ongoing Phase III SUNLIGHT trial (LONSURF + bevacizumab versus LONSURF in 3rd line mCRC) is proceeding as planned.”
Nearly 1.4 million people are diagnosed with colorectal cancer (CRC) each year worldwide,1 equating to 10% of the global cancer cases.1 In Europe, CRC is the second most common cause of cancer death,2 and metastatic (when the cancer has spread from the primary site to other parts of the body) patients have a 5-year survival rate of just 11%.2 Standard chemotherapy regimens for mCRC include fluoropyrimidines, oxaliplatin, irinotecan or targeted treatments, such as those that target vascular endothelial growth factors (VEGF) or endothelial growth factor receptors (EGFR).
“Metastatic colorectal cancer patients who are not well enough to undergo intensive chemotherapy have limited options, and quality of life is a priority,” said Professor Thierry André, MD, Saint Antoine Hospital, Paris, France, and Lead Investigator for the SOLSTICE study. “We are continuously searching for new ways to give these patients efficient treatment with low toxicities.”
Servier is committed to developing new treatments to support patients in their fight against gastrointestinal cancer.
#ENDS#
About SOLSTICE
SOLSTICE is an open-label, randomized, multicentre Phase III trial in 856 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy. Patients were randomized 1:1 to receive 1st
line LONSURF + bevacizumab versus capecitabine + bevacizumab. The primary objective is to demonstrate superior progression free survival with LONSURF + bevacizumab over capecitabine + bevacizumab. The first patient was enrolled in March 2019.
For more information on SOLSTICE, please visit www.ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/show/NCT03869892 ). The ClinicalTrials.gov Identifier is NCT03869892.
About LONSURF
LONSURF
consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.
In the EU, LONSURF is indicated as monotherapy for the treatment of adult patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti- VEGF agents, and anti-EGFR agents. LONSURF is also indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer (mGC), including adenocarcinoma of the gastroesophageal junction (mGEJC), who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
As of October 2021, LONSURF has been approved in 96 countries for the treatment of advanced mCRC and in 80 countries for the treatment of advanced mGC/mGEJC.
LONSURF was discovered and developed by Taiho Pharmaceutical Co., Ltd. In June 2015, Taiho Pharmaceutical and Servier entered into an exclusive license agreement for the co-development and commercialization of LONSURF in Europe and other countries outside of the United States, Canada, Mexico, and Asia.
About Servier
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities, from research to support beyond the pill.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: servier.com .
Follow us on Social Media:
LinkedIn
Facebook
Twitter
Instagram
References
1
Digestive Cancers Europe. Prevalence of Colorectal Cancer. Available at: https://digestivecancers.eu/colorectal-cancer/prevalence-of-colorectal-cancer-prevalence/?menu_id=13873
Last accessed: October 2021.
2
World Health Organisation. GLOBOCAN. Cancer today. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages. Available at: https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D
Last accessed: October 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211022005006/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance24.4.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Nemluvio Broad-based growth: Strong performance momentum across product categories and across geographies, with constant currency year-on-year growth of 9.9% for Injectable Aesthetics, 7.8% for Dermatological Skincare, and 4.9% for Therapeutic Dermatology, which includes net sales of 39 million USD for Nemluvio® (nemolizumab) Innovation, science and education leadership: Further advanced its category leadership in dermatology: with the launch of Nemluvio and Relfydess™ (RelabotulinumtoxinA),
Engelhart and e.optimum Strengthen Their Partnership With a Further Onshore Wind PPA, Supporting Germany’s Energy Transition24.4.2025 07:00:00 CEST | Press release
The Global Commodities and Renewable Energy Trader, Engelhart, is delighted to announce the signing of a further power purchase agreement (PPA) with e.optimum, one of Germany’s largest independent energy suppliers. Following the first PPA signed in January 2025, this new agreement secures renewable electricity from additional onshore wind turbines with a total capacity of approximately 167 MWfromJuly to December 2025. This is enough green power to supply around 31,000 households. This second PPA marks a significant expansion of the partnership between the two companies. It represents a 195% increase in contracted capacity, bringing the total from 86 MW to 253 MW of onshore wind power. Furthermore, the agreement contributes directly to Germany’s transition to a net zero-carbon economy by 2045. Matthias Seel, Senior Originator Corporate Customers Europe at Engelhart, commented: "The second PPA with e.optimum is another milestone in our joint partnership. Especially in uncertain economic
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management23.4.2025 17:42:00 CEST | Press release
Seamless Integration and Speed: Latest Innovations Empower Faster, Smarter, and Safer Software Security Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning. “Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom